Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 14, 2023

SELL
$14.2 - $23.75 $2.14 Million - $3.58 Million
-150,774 Reduced 38.93%
236,543 $4.49 Million
Q1 2023

May 15, 2023

BUY
$15.27 - $19.72 $2.77 Million - $3.58 Million
181,483 Added 88.17%
387,317 $6.01 Million
Q4 2022

Feb 14, 2023

BUY
$6.59 - $17.75 $1.36 Million - $3.65 Million
205,834 New
205,834 $3.65 Million
Q1 2022

May 16, 2022

SELL
$5.06 - $8.77 $912,798 - $1.58 Million
-180,395 Closed
0 $0
Q4 2021

Feb 14, 2022

SELL
$7.33 - $9.32 $1.36 Million - $1.73 Million
-185,398 Reduced 50.68%
180,395 $1.54 Million
Q3 2021

Nov 15, 2021

SELL
$7.01 - $11.37 $20,581 - $33,382
-2,936 Reduced 0.8%
365,793 $3.18 Million
Q2 2021

Aug 16, 2021

SELL
$9.4 - $16.85 $576,088 - $1.03 Million
-61,286 Reduced 14.25%
368,729 $3.9 Million
Q1 2021

May 17, 2021

BUY
$13.08 - $49.6 $5.62 Million - $21.3 Million
430,015 New
430,015 $6.9 Million

Others Institutions Holding IMVT

About Immunovant, Inc.


  • Ticker IMVT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 129,077,000
  • Market Cap $3.55B
  • Description
  • Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...
More about IMVT
Track This Portfolio

Track Voloridge Investment Management, LLC Portfolio

Follow Voloridge Investment Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Voloridge Investment Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Voloridge Investment Management, LLC with notifications on news.